
    
      This study is a post-marketing surveillance to monitor safety and efficacy of ropinirole
      during using of treatment for RLS(restless leg syndrome) and identify SAEs, adverse drug
      reactions, and unexpected AEs not described as precautions or warnings and to identify
      prognostic factors that have an effect on the AEs and to assess effectiveness of ropinirole
      in real clinical practices after marketing. The subjects are patients prescribed for
      ropinirole by the investigators at the sites based on prescription information in normal
      clinical practices.
    
  